Importantly, ARN‐3236, an oral SIK2 inhibitor, significantly increases the radiosensitivity of CRC cells, both in vitro and in vivo, emerging as a potential radiosensitizer in CRC treatment (Figure 7). This evidence concerns the gene SIK2 and colorectal carcinoma.